Home⇛Science Asia Review⇛vol. 8 no. 1 (2023)

Anti-parasitic Drug Ivermectin in the treatment of COVID-19: A Review

Fatimae I. Mariano | Elizabeth Y Tan | Maria Donabelle U Dean

 

Abstract:

The World Health Organization declared COVID-19 a pandemic in March 2020. As nations began to issue measures to combat the spread of the virus, it also saw dreadful consequences impacting the different sectors of the community. The search for cure was underway but since drug development can take years, repurposing of existing potential drugs became a trend. Ivermectin, an antiparasitic drug, piqued the curiosity of researchers since the preclinical study done by Caly, et al in 2020 showed promising results on its effect against SARS-CoV 2 virus. This article looks into a collection of published studies whether or not Ivermectin, given as treatment for COVID-19, improves patient outcomes.



References:

  1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-rem arks-at-the-media-briefing-oncovid-19 11-march-2020
  2. Kumar, M., & Al Khodor, S. (2020). Pathophysiology and treatment strategies for COVID-19. Journal of translational medicine, 18(1), 353.
  3. Trougakos, I. P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O. E., Aivalioti, E., Paraskevis, D., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021). Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of biomedical science, 28(1), 9. https://doi.org/10.1186/s12929-020-00703-5
  4. Popp, M., Stegemann, M., Metzendorf, M. I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021). Ivermectin for preventing and treating COVID-19. The Cochrane database of systematic reviews, 7(7), CD015017. https://doi.org/10.1002/14651858.CD015017.pub2
  5. Caly et al. https://reader.elsevier.com/reader/sd/pii/S0166354220302011?token=5B2491C44E17B102C3F6812BB5E257F995AF87555F7543BEBDA54A52281294E88C2C8FF2DE39A26CFA9DF04A7E243BCC&originRegion=us-east1&originCreation=20220608095654
  6. M. Mansour SN., Shamma RA., Ahmed KA., Sabry NEsmat GA. Mahmoud A., and Maged A. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. International Immunopharmacology, (2021), 108004, 99. https://doi.org/10.1016/J.INTIMP.2021.1080047.
  7. Albariqi A., Wang Y., Chang R., Quan D., Wang X., Kalfas S., Drago J., Britton W., and Chan H. Pharmacokinetics and safety of inhaled vermectin in mice as a potential COVID-19 treatment. International Journal of Pharmaceutics, (2022), 121688, 619. https://doi.org/10.1016/J.IJPHARM.2022.121688
  8. Ravikirti, Roy, R., Pattadar, C., Raj, R., Agarwal, N., Biswas, B., Manjhi, P. K., Rai, D. K., Shyama, Kumar, A., & Sarfaraz, A. (2021). Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 24, 343–350. https://doi.org/10.18433/jpps32105
  9. Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M. C., Ojeda Fernandez, M. L., Alvisi, M. F., De Simone, I., Rulli, E., Nobili, A., Casalini, G., Antinori, S., Gobbi, M., Campoli, C., Deiana, M., Pomari, E., Lunardi, G., Tessari, R., & Bisoffi, Z. (2022). High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. International journal of antimicrobial agents, 59(2), 106516. https://doi.org/10.1016/j.ijantimicag.2021.106516
  10. Vallejos, J., Zoni, R., Bangher, M., Villamandos, S., Bobadilla, A., Plano, F., Campias, C., Chaparro Campias, E., Medina, M. F., Achinelli, F., Guglielmone, H. A., Ojeda, J., Farizano Salazar, D., Andino, G., Kawerin, P., Dellamea, S., Aquino, A. C., Flores, V., Martemucci, C. N., Martinez, S. M., … Aguirre, M. G. (2021). Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebocontrolled trial. BMC infectious diseases, 21(1), 635. https://doi.org/10.1186/s12879-021-06348-5
  11. Mohan, A., Tiwari, P., Suri, T. M., Mittal, S., Patel, A., Jain, A., Velpandian, T., Das, U. S., Boppana, T. K., Pandey, R. M., Shelke, S. S., Singh, A. R., Bhatnagar, S., Masih, S., Mahajan, S., Dwivedi, T., Sahoo, B., Pandit, A., Bhopale, S., Vig, S., … Guleria, R. (2021). Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A singlecentre randomized, placebo-controlled trial. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 27(12), 1743–1749. https://doi.org/10.1016/j.jiac.2021.08.02
  12. Pott-Junior H., Bastos Paoliello M., Miguel A., da Cunha A., de Melo Freire C., Neves F., da Silva de Avó L., Roscani M., dos Santos S., and Chachá S. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology Reports, (2021), 505-510, 8. https://doi.org/10.1016/J.TOXREP.2021.03.003
  13. Chaccour C., Casellas A., Blanco-Di Matteo A., Pineda I., FernandezMontero A., Ruiz-Castillo P., Richardson M., Rodríguez-Mateos M., Jordán-Iborra C., Brew J., Carmona-Torre ., Giráldez M., Laso ., Gabaldón-Figueira J., Dobaño C., Moncunill G., Yuste J., Del Pozo J., Rabinovich N., Schöning V., Hammann F., Reina G., Sadaba B., Fernández-Alonso M. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, (2021), 100720, 32. https://doi.org/10.1016/J.ECLINM.2020.100720
  14.  Shahbaznejad, L., Davoudi, A., Eslami, G., Markowitz, J. S., Navaeifar, M. R., Hosseinzadeh, F., Movahedi, F. S., & Rezai, M. S. (2021). Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. Clinical therapeutics, 43(6),1007–1019. https://doi.org/10.1016/j.clinthera.2021.04.007
  15. Shimizu K., Hirata H., Kabata D., Tokuhira N., Koide M., Ueda A., Tachino J., Shintani A., Uchiyama A., Fujino Y., Ogura H. Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis. Journal of Infection and Chemotherapy, (2022), 548-553, 28(4). https://doi.org/10.1016/J.JIAC.2021.12.024
  16. Abd-Elsalam, S., Noor, R. A., Badawi, R., Khalaf, M., Esmail, E. S., Soliman, S., Abd El Ghafar, M. S., Elbahnasawy, M., Moustafa, E. F., Hassany, S. M., Medhat, M. A., Ramadan, H. K., Eldeen, M., Alboraie, M., Cordie, A., & Esmat, G. (2021). Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. Journal of medical virology, 93(10), 5833–5838. https://doi.org/10.1002/jmv.27122
  17. Shahbaznejad, L., Davoudi, A., Eslami, G., Markowitz, J. S., Navaeifar, M. R., Hosseinzadeh, F., Movahedi, F. S., & Rezai, M. S. (2021). Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical therapeutics, 43(6), 1007-1019 https://doi.org/10.1016/j.clinthera.2021,04.007
  18. Okumuş N., Demirtürk, N., Çetinkaya, R. A., Güner, R., Avcı, İ. Y., Orhan, S., Konya, P., Şaylan, B., Karalezli, A., Yamanel, L., Kayaaslan, B., Yılmaz, G., Savaşçı, Ü., Eser, F., & Taşkın, G. (2021). Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC infectious diseases, 21(1), 411. https://doi.org/10.1186/s12879-021-06104-9
  19. Mahmud, R., Rahman, M. M., Alam, I., Ahmed, K., Kabir, A., Sayeed, S., Rassel, M. A., Monayem, F. B., Islam, M. S., Islam, M. M., Barshan, A. D., Hoque, M. M., Mallik, M. U., Yusuf, M. A., & Hossain, M. Z. (2021). Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. The Journal of international medical research, 49(5), 3000605211013550. https://doi.org/10.1177/03000605211013550
  20. Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S. (2022). Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, doseresponse study in Lagos. QJM : monthly journal of the Association of Physicians, 114(11), 780–788. https://doi.org/10.1093/qjmed/hcab035
  21. Galan, L., Santos, N., Asato, M. S., Araújo, J. V., de Lima Moreira, A., Araújo, A., Paiva, A., Portella, D., Marques, F., Silva, G., de Sousa Resende, J., Tizolim, M. R., Santos, P. L., Buttenbender, S. F., de Andrade, S. B., Carbonell, R., Da Rocha, J. G., de Souza, R., & da Fonseca, A. J. (2021). Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathogens and global health, 115(4), 235–242. https://doi.org/10.1080/20477724.2021.1890887
  22.  Aref, Z. F., Bazeed, S., Hassan, M. H., Hassan, A. S., Rashad, A., Hassan, R. G., & Abdelmaksoud, A. A. (2021). Clinical, Biochemical nd Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. International journal of nanomedicine, 16, 4063–4072. https://doi.org/10.2147/IJN.S313093
  23. Procter, B. C., Ross, C., Pickard, V., Smith, E., Hanson, C., & McCullough, P. A. (2020). Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in cardiovascular medicine, 21(4), 611–614. https://doi.org/10.31083/j.rcm.2020.04.260
  24. Cadegiani F., Goren A., Wambier C., and McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes and New Infections, (2021), 100915, 43. https://doi.org/10.1016/J.NMNI.2021.100915
  25. Lima-Morales R., Méndez-Hernández P., Flores Y., OsornoRomero P., Cuecuecha-Rugerio E., Nava-Zamora A., HernándezGaldamez D., Romo-Dueñas D., and Salmerón J. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International Journal of Infectious Diseases, (2021), 598-605, 105. https://doi.org/10.1016/J.IJID.2021.02.014
  26. Pott-Junior H., Bastos Paoliello M., Miguel A., da Cunha A., de Melo Freire C., Neves F., da Silva de Avó L., Roscani M., dos Santos S., and Chachá S. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology Reports, (2021), 505-510, 8. https://doi.org/10.1016/J.TOXREP.2021.03.003
  27. Hazan, S., Dave, S., Gunaratne A., Dolai, S., Clancy, R., McCullough, P., and Borody, T. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. Future Microbiology. (2022) 17(5), 339–350. https://doi.org/10.2217/fmb2022-0014
  28. Zein, A., Sulistiyana, C. S., Raffaelo, W. M., & Pranata, R. (2021). Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes & metabolic syndrome, 15(4), 102186. https://doi.org/10.1016/j.dsx.2021.102186
  29. Roman, Y. M., Burela, P. A., Pasupuleti, V., Piscoya, A., Vidal, J. E., & Hernandez, A. V. (2021). Ivermectin for the treatment of COVID19: A systematic review and meta-analysis of randomized controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ciab591. Advance online publication. https://doi.org/10.1093/cid/ciab591
  30. Padhy, B. M., Mohanty, R. R., Das, S., & Meher, B. R. (2020). Therapeutic potential of ivermectin as add-on treatment in COVID 19: A systematic review and meta-analysis. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 23, 462–469. https://doi.org/10.18433/jpps31457
  31. Bestetti, R. B., Furlan-Daniel, R., & Silva, V. (2021). Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review. International journal of environmental research and public health, 18(13), 7212. https://doi.org/10.3390/ijerph18137212.
  32. Chaudhry, M. W., Zubair, S. M., Zubairi, A., & Irfan, M. (2021). Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature. Advances in respiratory medicine, 89(4), 413–418. https://doi.org/10.5603/ARM.a2021.008

Tools


Copyright © 2024  KITE Digital Educational Solutions |  Exclusively distributed by CE-Logic